Aging, Geriatric Syndromes and Clonal Hematopoiesis
Study Details
Study Description
Brief Summary
In this study the investigators will incorporate a wide range of clinical variables associated with aging and cardiovascular disease to determine whether they are associated with mutation status independent of chronologic age. Clinically, aging can be operationalized using geriatric assessment, which entails a comprehensive multi-dimensional assessment of the health of an older adult, including measures of comorbidity, polypharmacy, functional status, cognition, depression, falls, social activities and social support. Given that aging is heterogeneous, geriatric assessment allows greater specificity for aging than chronological age alone.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Arm A: Clonal hematopoiesis Complete several self-administered health assessments at baseline and every 6 months until death. Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death. Peripheral blood draw will occur at baseline and no more than every 6 months until death. Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death May be approached about optional bone marrow biopsy |
Other: Cognitive Assessment
-Baseline and no more frequently than every 6 months until death
Other: Activities of Daily Living Questionnaire
10 items about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Instrumental Activities of Daily Living, subscale of the OARS
7 items about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Karnofsky Self-reported Performance Rating Scale
1 item about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Number of Falls
1 item about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Physical Health Section, subscale of the OARS
13 items about comorbidity
Baseline and no more frequently than every 6 months until death
Other: MOS Social Activity Survey
4 items about social activity
Baseline and no more frequently than every 6 months until death
Other: Unintentional Weight Loss
2 items about nutrition
Baseline and no more frequently than every 6 months until death
Genetic: Peripheral Blood Draw
-Baseline and no more frequently than every 6 months until death
Genetic: Buccal Swab
Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)
Baseline and no more frequently than every 6 months until death
Other: Heart Health and Smoking History from BRFSS questionnaire
7 items about heart health and smoking history
Baseline and no more frequently than every 6 months until death
Other: Gait Speed
Research coordinator will test gait speed
Baseline and no more frequently than every 6 months until death
Other: Grip Strength
Research coordinator will test grip strength
Baseline and no more frequently than every 6 months until death
Other: Height and Weight measurements
-Baseline and no more frequently than every 6 months until death
Other: Blood pressure measurement
-Baseline and no more frequently than every 6 months until death
Procedure: Optional bone marrow biopsy
-1 optional bone marrow biopsy
|
Arm B: No clonal hematopoiesis Complete several self-administered health assessments at baseline and every 6 months until death. Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death. Peripheral blood draw will occur at baseline and no more than every 6 months until death. Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death May be approached about optional bone marrow biopsy |
Other: Cognitive Assessment
-Baseline and no more frequently than every 6 months until death
Other: Activities of Daily Living Questionnaire
10 items about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Instrumental Activities of Daily Living, subscale of the OARS
7 items about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Karnofsky Self-reported Performance Rating Scale
1 item about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Number of Falls
1 item about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Physical Health Section, subscale of the OARS
13 items about comorbidity
Baseline and no more frequently than every 6 months until death
Other: MOS Social Activity Survey
4 items about social activity
Baseline and no more frequently than every 6 months until death
Other: Unintentional Weight Loss
2 items about nutrition
Baseline and no more frequently than every 6 months until death
Genetic: Peripheral Blood Draw
-Baseline and no more frequently than every 6 months until death
Genetic: Buccal Swab
Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)
Baseline and no more frequently than every 6 months until death
Other: Heart Health and Smoking History from BRFSS questionnaire
7 items about heart health and smoking history
Baseline and no more frequently than every 6 months until death
Other: Gait Speed
Research coordinator will test gait speed
Baseline and no more frequently than every 6 months until death
Other: Grip Strength
Research coordinator will test grip strength
Baseline and no more frequently than every 6 months until death
Other: Height and Weight measurements
-Baseline and no more frequently than every 6 months until death
Other: Blood pressure measurement
-Baseline and no more frequently than every 6 months until death
Procedure: Optional bone marrow biopsy
-1 optional bone marrow biopsy
|
Arm C: No clonal hematopoiesis & no follow-up Complete several self-administered health assessments at baseline with no further follow-up Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up Peripheral blood draw will occur at baseline with no further follow-up Buccal swabs will occur at baseline with no further follow-up |
Other: Cognitive Assessment
-Baseline and no more frequently than every 6 months until death
Other: Activities of Daily Living Questionnaire
10 items about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Instrumental Activities of Daily Living, subscale of the OARS
7 items about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Karnofsky Self-reported Performance Rating Scale
1 item about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Number of Falls
1 item about daily functional status
Baseline and no more frequently than every 6 months until death
Other: Physical Health Section, subscale of the OARS
13 items about comorbidity
Baseline and no more frequently than every 6 months until death
Other: MOS Social Activity Survey
4 items about social activity
Baseline and no more frequently than every 6 months until death
Other: Unintentional Weight Loss
2 items about nutrition
Baseline and no more frequently than every 6 months until death
Genetic: Peripheral Blood Draw
-Baseline and no more frequently than every 6 months until death
Genetic: Buccal Swab
Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)
Baseline and no more frequently than every 6 months until death
Other: Heart Health and Smoking History from BRFSS questionnaire
7 items about heart health and smoking history
Baseline and no more frequently than every 6 months until death
Other: Gait Speed
Research coordinator will test gait speed
Baseline and no more frequently than every 6 months until death
Other: Grip Strength
Research coordinator will test grip strength
Baseline and no more frequently than every 6 months until death
Other: Height and Weight measurements
-Baseline and no more frequently than every 6 months until death
Other: Blood pressure measurement
-Baseline and no more frequently than every 6 months until death
|
Arm D: Hip replacement Complete several self-administered health assessments at baseline and every 6 months until death. Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death. Participants with or without clonal hematopoiesis who are undergoing hip replacement Peripheral blood draw will occur at baseline and no more than every 6 months until death. Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death May be approached about optional bone marrow biopsy |
|
Arm E: Trauma -Blood sample at the time of admission with initial bloodwork. For inpatient participants, weekly follow-up samples will be drawn with morning phlebotomy. A follow-up sample collection will occur 4-7 weeks after discharge. |
Procedure: Blood draw for trauma measurements
-For Arm E only
|
Outcome Measures
Primary Outcome Measures
- Background mutation rate in hematopoietic stem cells from older adults regardless of a prior cancer diagnosis as measured by the number and frequency of hematopoietic-specific mutations [Estimated to be 10 years]
-The investigators will sequence the coding region of some or all of the genes in an individual's blood cells and compare results to their matched mouth cells to define hematopoietic-specific mutations. The number of hematopoietic-specific mutations per individual and the frequency of individuals with mutations will be measured.
- Presence or absence of geriatric syndromes as measured by hematopoietic stem cell mutations [Estimated to be 10 years]
-The presence or absence of geriatric syndromes will be correlated with the mutation status of individuals.
- Determine the natural history of mutations in older adults with clonal hematopoiesis as measured by risk to develop blood cancer/geriatric syndrome/illness/cardiovascular disease [Estimated to be 10 years]
-Individuals with mutations will be followed longitudinally to monitor the fraction of hematopoietic cells with mutations, the functional consequences of mutations in their blood cells, and the risk of developing a blood cancer, geriatric syndrome, cardiovascular disease, or other illness.
- Presence or absence of cardiovascular disease as measured by hematopoietic stem call mutations [Estimated to be 10 years]
- Determine whether expansion of clonal hematopoiesis (CH) occurs following acute trauma [Estimated to be 10 years]
-Measures change in variant allele fraction
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least 50 years of age.
-
Able to understand written and spoken English.
-
Able to understand and willing to sign an IRB-approved written informed consent document (or that of a legally authorized representative, if applicable for the trauma cohort)
Exclusion Criteria:
-
Inability or unwillingness to complete health questionnaire.
-
History of a recent (<30 days) acute viral illness.
-
Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation therapy. A prior history of cancer is allowed if the participant completed therapy > 1 year prior to enrollment; participants with a prior diagnosis of cancer will be asked to sign a release of information for the research team to obtain records regarding their prior cancer treatment.
-
Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the treatment of a non-malignant disease.
-
Vulnerable populations (e.g. prisoners).
-
Known infection with Hepatitis B or C, HTLV, or HIV.
-
Additional exclusion for optional bone marrow aspirate/biopsy substudy:
-
Use of medications for anticoagulation or "blood thinning" including warfarin, low molecular weight heparins (enoxaparin, daltaparin) or direct-acting oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban or betrixaban)
-
allergy to lidocaine or other local anesthetics.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
Sponsors and Collaborators
- Washington University School of Medicine
- Edward P. Evans Foundation
Investigators
- Principal Investigator: Meagan Jacoby, M.D., Washington University School of Medicine
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 201511019